BIRMINGHAM, Ala., Jan. 14, 2020 /PRNewswire/ -- AI Metrics, LLC is
partnering with UK-based IQ-AI Limited (LON:IQAI) to distribute AI
Metrics' virtual liver biopsy software, a first-of-its-kind
platform. The global distribution agreement with IQ-AI
subsidiary Imaging Biometrics will enable chronic liver disease
(CLD) assessment using commonly acquired CT images.
Over 20 million deaths worldwide are attributed to CLD,
primarily from non-alcoholic fatty liver disease. AI Metrics
developed LSN technology to non-invasively assess the nodules, or
bumps, on the liver's surface. This information, when used by
trained clinicians, may aid in the diagnosis and staging of
CLD.
For patients, this is great news. Currently, clinicians assess
patient liver condition via surgical biopsy, which is prone to
sampling error, pain, bleeding, and other complications.
Alternatively, specialized MRI or ultrasound equipment can be used
in certain cases, but patient fasting is required. In
contrast, LSN analysis uses common CT scanning technology and
proprietary software for accurate, low risk assessment of
CLD. Furthermore, prior CT scans can be used to retroactively
assess disease progression.
AI Metrics enlisted the services of Imaging Biometrics to help
complete the translation of the LSN technology to routine clinical
and research use. Along with software development services, IB
offered its regulatory expertise and is assisting AI Metrics in
seeking CE Mark and FDA 510(k) clearance for marketing in
Europe and the U.S.,
respectively.
"We are excited about partnering with Imaging Biometrics as we
introduce LSN technology to the worldwide market," said AI Metrics
CEO Andrew Smith, MD PhD. "Their
development efforts have been integral to bringing LSN from
promising research to commercial introduction, and the continuity
of our relationship moving forward will ensure that LSN can quickly
gain widespread utilization."
About AI Metrics: www.aimetrics.com
AI Metrics is an early stage company developing AI-driven
innovations in radiology image analysis, founded by radiology
researcher Andrew Smith, MD
PhD. The company's products enhance workflow speed and
reduce costs, while improving data quality for clinical and
research efforts, and ultimately, for improved physician
collaboration and patient care.
About Imaging Biometrics:
www.imagingbiometrics.com
Imaging Biometrics, a subsidiary of IQ-AI Limited (LON:IQAI),
develops and provides visualization and analytical solutions in
collaboration with top researchers and clinicians in
radiology. The company's platform-independent software
plug-ins extend the base functionality of workstations, imaging
systems, PACS, and seamlessly integrate into routine workflows.
View original
content:http://www.prnewswire.com/news-releases/ai-metrics-and-imaging-biometrics-strike-agreement-300985983.html
SOURCE AI Metrics, LLC